Royal Bank Of Canada restated their hold rating on shares of Hologic, Inc. (NASDAQ:HOLX) in a research note issued to investors on Friday morning. They currently have a $42.00 target price on the medical equipment provider’s stock.

A number of other analysts have also recently commented on the stock. BidaskClub cut shares of Hologic from a hold rating to a sell rating in a research report on Wednesday, August 9th. Barclays PLC reaffirmed an equal weight rating and set a $51.00 price target (down previously from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Hologic from a sell rating to a hold rating in a research report on Friday, August 4th. Deutsche Bank AG cut their price target on shares of Hologic from $51.00 to $49.00 and set a buy rating on the stock in a research report on Thursday, August 3rd. Finally, Goldman Sachs Group, Inc. (The) cut shares of Hologic from a conviction-buy rating to a buy rating and cut their price target for the company from $48.00 to $47.00 in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $48.43.

Hologic (NASDAQ HOLX) opened at 37.36 on Friday. The firm’s 50-day moving average price is $38.51 and its 200 day moving average price is $42.54. The company has a market capitalization of $10.48 billion, a price-to-earnings ratio of 13.91 and a beta of 0.92. Hologic has a 12-month low of $35.15 and a 12-month high of $46.80.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.51 earnings per share. On average, analysts expect that Hologic will post $2.01 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/26/hologic-inc-holx-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

In related news, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Karleen Marie Oberton sold 4,704 shares of the company’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. Insiders have sold a total of 27,594 shares of company stock worth $1,168,871 in the last three months. Insiders own 0.79% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Hologic by 4.2% in the 2nd quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock worth $1,340,850,000 after acquiring an additional 1,200,825 shares during the last quarter. State Street Corp raised its holdings in shares of Hologic by 1.5% in the 1st quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock worth $540,846,000 after acquiring an additional 189,572 shares during the last quarter. Capital World Investors acquired a new stake in shares of Hologic in the 2nd quarter worth about $312,441,000. Victory Capital Management Inc. raised its holdings in shares of Hologic by 23.7% in the 2nd quarter. Victory Capital Management Inc. now owns 5,012,352 shares of the medical equipment provider’s stock worth $227,461,000 after acquiring an additional 961,528 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Hologic by 6.6% in the 2nd quarter. Bank of Montreal Can now owns 3,418,319 shares of the medical equipment provider’s stock worth $155,123,000 after acquiring an additional 211,550 shares during the last quarter. Institutional investors own 96.38% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.